Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis

Reproductive Toxicology

Volumn 52, Issue , 2015, Pages 78-82

  Alsaad, Abdulaziz M S ^a,b,c   Kaplan, Yusuf C ^a,d   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

Author keywords

Cardiovascular defects; Fluconazole; Infants; Pregnancy; Teratogenicity; Vulvovaginal candidiasis

Indexed keywords

FLUCONAZOLE; ANTIFUNGAL AGENT;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HUMAN; LIMB DEFECT; LOW DRUG DOSE; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; PROGENY; REPRODUCTION; RISK FACTOR; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; VAGINA CANDIDIASIS; ABNORMALITIES, DRUG-INDUCED; CANDIDIASIS, VULVOVAGINAL; CHEMICALLY INDUCED; CRANIOFACIAL ABNORMALITIES; FEMALE; HEART DEFECTS, CONGENITAL; MEDLINE; META ANALYSIS; PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ANTIFUNGAL AGENTS; CANDIDIASIS, VULVOVAGINAL; CRANIOFACIAL ABNORMALITIES; FEMALE; FLUCONAZOLE; HEART DEFECTS, CONGENITAL; HUMANS; MEDLINE; PREGNANCY; PREGNANCY TRIMESTER, FIRST;

EID: 84924311183     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2015.02.009     Document Type: Article

References (19)

1. Sobel J.D., Faro S., Force R.W., Foxman B., Ledger W.J., Nyirjesy P.R., et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998, 178(2):203-211.
2. Mendling W., Brasch J. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses 2012, 55(Suppl 3):1-13. German Society for G, Obstetrics, Working Group for I, Infectimmunology in GWorking Group for I, Infectimmunology in G.
3. Sobel J.D. Vulvovaginal candidosis. Lancet 2007, 369(9577):1961-1971.
4. Tooley P.J. Patient and doctor preferences in the treatment of vaginal candidosis. Practitioner 1985, 229(1405):655-660.
5. Watson M.C., Grimshaw J.M., Bond C.M., Mollison J., Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated Vulvovaginal candidiasis (thrush): a systematic review. BJOG 2002, 109(1):85-95.
6. Finer L.B., Zolna M.R. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011, 84(5):478-485.
7. Jick S.S. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999, 19(2):221-222.
8. Mastroiacovo P., Mazzone T., Botto L.D., Serafini M.A., Finardi A., Caramelli L., et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996, 175(6):1645-1650.
9. Molgaard-Nielsen D., Pasternak B., Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013, 369(9):830-839.
10. Norgaard M., Pedersen L., Gislum M., Erichsen R., Sogaard K.K., Schonheyder H.C., et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother 2008, 62(1):172-176.
11. Campomori A., Bonati M. Fluconazole treatment for Vulvovaginal candidiasis during pregnancy. Ann Pharmacother 1997, 31(1):118-119.
12. Inman W., Pearce G., Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study: with special reference to the outcome of pregnancy. Eur J Clin Pharmacol 1994, 46(2):115-118.
13. Wilton L.V., Pearce G.L., Martin R.M., Mackay F.J., Mann R.D. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998, 105(8):882-889.
14. Lee B.E., Feinberg M., Abraham J.J., Murthy A.R. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J 1992, 11(12):1062-1064.
15. Lopez-Rangel E., Van Allen M.I. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005, 73(11):919-923.
16. Pursley T.J., Blomquist I.K., Abraham J., Andersen H.F., Bartley J.A. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996, 22(2):336-340.
17. Aleck K.A., Bartley D.L. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997, 72(3):253-256.
18. Wells GA, SB, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available: . Accessed 25 November 2012. (2011). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
19. Pfizer, Diflucan® [product monograph]. New York, NY: Pfizer Inc.; 2013.